Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Anti-CD3/MUC1-armed cytokine induced killer cells-Benhealth Biopharmaceutical (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 10 Sep 2019 Planned primary completion date changed from 5 Apr 2019 to 5 Apr 2021.
- 10 Sep 2019 Planned initiation date (estimated date for recruitment of the first subject) changed to 5 Apr 2020.
- 17 May 2018 New trial record